Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293359 | 1.00 | ACACB (0.47) | ACACBACACAPPARGPPARASRD5A2 | |
| Hydrochloric Acid SCHEMBL2291285 | 0.98 | ACACB (0.46) | ACACBACACAPPARGPPARASRD5A2 | |
| SCHEMBL12379288 | 0.94 | LTA4H (0.53) | ACACBPPARGPPARASRD5A2LTA4H | |
| Hydrochloric Acid SCHEMBL2296186 | 0.92 | LTA4H (0.51) | ACACBPPARGPPARASRD5A2LTA4H | |
| SCHEMBL12379296 | 0.87 | LTA4H (0.50) | PPARGPPARALTA4HSIGMAR1 | |
| SCHEMBL693965 | 0.85 | MAPK1 (0.57) | CYP3A4MAPK1OPRD1OPRK1TAAR1 | |
| SCHEMBL1396350 | 0.85 | MAPK1 (0.57) | CYP3A4MAPK1OPRD1OPRK1TAAR1 | |
| SCHEMBL1908735 | 0.85 | MAPK1 (0.57) | CYP3A4MAPK1OPRD1OPRK1TAAR1 | |
| SCHEMBL17923855 | 0.84 | LTA4H (0.52) | PPARGPPARALTA4HSIGMAR1 | |
| SCHEMBL13191914 | 0.84 | LTA4H (0.52) | PPARGPPARALTA4HSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989480-B2 | Aryl amino acid derivatives as inhibitors for treating inflammation | DECODE GENETICS EHF (IS) | 2011-08-02 | — | — | US | disclosed |
| EP-2066800-A2 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008019306-A2 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2008-02-14 | — | — | WO | disclosed |
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | LTA4H, LTB4R2, LTB4R | ACACB 1829/4885ACACA 1249/4885PPARG 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.